Craif, a bio-AI spin-off from Nagoya University, is preparing a regulatory filing in Japan for miSignal, a urine-based AI test designed to detect pancreatic cancer. If approved, the company said it would be the first approved urine-based pancreatic cancer test worldwide. Craif is also preparing to launch miSignal in the U.S. following a $33 million Series D funding round.
The test analyzes microRNA in urine using an AI model. In a study published in eClinicalMedicine, the model detected pancreatic cancer across disease stages, including early-stage disease, with sensitivity and specificity exceeding 90%. Craif is expanding R&D at its San Diego laboratory and plans a prospective clinical study to support regulatory and reimbursement requirements in the U.S.
For patients and providers, miSignal could offer a non-invasive approach to earlier pancreatic cancer detection while supporting broader efforts to apply AI and molecular diagnostics to difficult-to-detect diseases.
Image Credit: Craif
Key Themes Behind This Trend
- Urine-based Cancer Screening
- Non-invasive sample collection creates room for earlier disease detection models that fit routine care and expand access beyond specialized diagnostic settings.
- AI Molecular Diagnostics
- Machine learning applied to microRNA and other biomarkers is reshaping how hard-to-detect cancers are identified before conventional symptoms or imaging findings appear.
- Early-stage Oncology Detection
- High-sensitivity tests for aggressive cancers are opening pathways for preventive oncology programs built around screening, risk stratification, and reimbursable clinical workflows.
Where This Applies
- Biotechnology
- Bio-AI platforms are creating new value in biomarker discovery by combining molecular science, clinical validation, and software-driven diagnostic interpretation.
- Healthcare Diagnostics
- Laboratories and diagnostic providers face emerging opportunities around scalable, non-invasive cancer testing that supports faster physician decision-making and patient monitoring.
- Digital Health
- AI-enabled test platforms are extending digital health beyond apps into regulated clinical products that connect data science with real-world disease detection.
